

GLAXOSMITHKLINE PLC  
Form 6-K  
October 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
- b) Position/status CEO Designate
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882  
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£16.9675	447.196
- d) Aggregated information  
Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |    |   |   |           |
|----|---|---|-----------|
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882<br>Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to |           |
| b) | Nature of the transaction               | shareholders on 13 October 2016, on Ordinary Shares held in the Company's Deferred Investment Award Programme.  |           |
| c) | Price(s) and volume(s)                  | Price(s)  | Volume(s) |
|    |   | £16.9675  | 178.878   |
| d) | Aggregated information                  | n/a (single transaction)  |           |
| e) | Aggregated volume Price                 |   |           |
| e) | Date of the transaction                 | 2016-10-13  |           |
| f) | Place of the transaction                | n/a   |           |

1. Details of PDMR/person closely associated with them ('PCA')

- |    |                                    |                                   |
|----|------------------------------------|-----------------------------------|
| a) | Name                               | Mr S A Hussain                    |
| b) | Position/status                    | President, Global Pharmaceuticals |
| c) | Initial notification/<br>amendment | Initial notification              |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |    |      |                      |
|----|------|----------------------|
| a) | Name | GlaxoSmithKline plc  |
| b) | LEI  | 5493000HZTVUYLO1D793 |

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |    |   |   |           |
|----|---|---|-----------|
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882<br>Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to |           |
| b) | Nature of the transaction               | shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.   |           |
| c) | Price(s) and volume(s)                  | Price(s)  | Volume(s) |
|    |   | £16.9675  | 223.598   |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- d) Aggregated information n/a (single transaction)  
 Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr B McNamara  
 CEO, GSK Consumer  
 Healthcare
- b) Position/status
- c) Initial notification/  
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument GlaxoSmithKline plc  
 American Depositary Shares ('ADSs')  
 ISIN: US37733W1053  
 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s)  | Volume(s) |
|-----------|-----------|
| \$42.0900 | 284.061   |
- d) Aggregated information n/a (single transaction)  
 Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern  
 b) Position/status Chief Strategy Officer
- c) Initial notification/  
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument

	Ordinary shares of 25 pence each ('Ordinary Shares')				
	ISIN: GB0009252882				
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.9675</td> <td>178.878</td> </tr> </table>	Price(s)	Volume(s)	£16.9675	178.878
Price(s)	Volume(s)				
£16.9675	178.878				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2016-10-13				
f) Place of the transaction	n/a				

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	Senior Vice President, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')				
	ISIN: GB0009252882				
	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.				
b) Nature of the transaction	shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.9675</td> <td>178.878</td> </tr> </table>	Price(s)	Volume(s)	£16.9675	178.878
Price(s)	Volume(s)				
£16.9675	178.878				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2016-10-13				

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance  
President, Pharmaceuticals  
R&D
- b) Position/status
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882  
Increase in notional interest  
in Ordinary Shares following  
the re-investment of  
dividends paid to  
shareholders on 13 October  
2016 on Ordinary Shares held  
in the Company's Deferred  
Investment Award  
Programme.
- b) Nature of the transaction
- c) Price(s) and  
volume(s) Price(s) Volume(s)  
£16.9675 223.598
- d) Aggregated information  
Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 17, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc